用于鼻内和吸入式疫苗递送的生物材料。
Biomaterials for intranasal and inhaled vaccine delivery.
作者信息
Cahn Devorah, Amosu Mayowa, Maisel Katharina, Duncan Gregg A
机构信息
Fischell Department of Bioengineering, University of Maryland, College Park, MD, USA.
These authors contributed equally: Devorah Cahn, Mayowa Amosu.
出版信息
Nat Rev Bioeng. 2023 Feb;1(2):83-84. doi: 10.1038/s44222-022-00012-6. Epub 2023 Jan 24.
Abstract
Delivery of vaccines by nasal sprays may enable more robust, protective mucosal immune responses against infectious diseases, such as COVID-19, compared with intramuscular injection. In this Comment, we highlight how biomaterials can be designed to allow intranasal and inhaled vaccination.
摘要
与肌肉注射相比，通过鼻喷雾剂递送疫苗可能会引发针对诸如新冠病毒病等传染病更强大的保护性黏膜免疫反应。在本评论文章中，我们着重介绍了如何设计生物材料以实现鼻内和吸入式疫苗接种。
相似文献
1
Biomaterials for intranasal and inhaled vaccine delivery.用于鼻内和吸入式疫苗递送的生物材料。
Nat Rev Bioeng. 2023 Feb;1(2):83-84. doi: 10.1038/s44222-022-00012-6. Epub 2023 Jan 24.
2
Mucosal Immunity and Protective Efficacy of Intranasal Inactivated Influenza Vaccine Is Improved by Chitosan Nanoparticle Delivery in Pigs.壳聚糖纳米粒给药可提高鼻内接种流感灭活疫苗黏膜免疫和保护效果。
Front Immunol. 2018 May 2;9:934. doi: 10.3389/fimmu.2018.00934. eCollection 2018.
3
Human immune responses elicited by an intranasal inactivated H5 influenza vaccine.经鼻腔接种的灭活 H5 流感疫苗诱导的人体免疫应答。
Microbiol Immunol. 2020 Apr;64(4):313-325. doi: 10.1111/1348-0421.12775. Epub 2020 Mar 29.
4
Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial.鼻内接种腺病毒载体 COVID-19 疫苗的耐受性和免疫原性：一项开放性、部分随机、递增剂量的 I 期临床试验。
EBioMedicine. 2022 Nov;85:104298. doi: 10.1016/j.ebiom.2022.104298. Epub 2022 Oct 10.
5
Nasally inhaled therapeutics and vaccination for COVID-19: Developments and challenges.用于新型冠状病毒肺炎的鼻腔吸入疗法和疫苗接种：进展与挑战
MedComm (2020). 2021 Dec 14;2(4):569-586. doi: 10.1002/mco2.101. eCollection 2021 Dec.
6
Intranasal Subunit Vaccination Strategies Employing Nanomaterials and Biomaterials.鼻腔内亚单位疫苗接种策略采用纳米材料和生物材料。
ACS Biomater Sci Eng. 2021 May 10;7(5):1765-1779. doi: 10.1021/acsbiomaterials.0c01291. Epub 2020 Dec 16.
7
Intranasal administration of a single dose of MVA-based vaccine candidates against COVID-19 induced local and systemic immune responses and protects mice from a lethal SARS-CoV-2 infection.鼻内给予一剂基于 MVA 的 COVID-19 候选疫苗可诱导局部和全身免疫应答，并可保护小鼠免受致死性 SARS-CoV-2 感染。
Front Immunol. 2022 Sep 12;13:995235. doi: 10.3389/fimmu.2022.995235. eCollection 2022.
8
Nasal vaccine as a booster shot: a viable solution to restrict pandemic?鼻用疫苗作为加强针：限制疫情的可行解决方案？
Clin Exp Vaccine Res. 2022 May;11(2):184-192. doi: 10.7774/cevr.2022.11.2.184. Epub 2022 May 31.
9
Intranasal and sublingual delivery of inactivated polio vaccine.灭活脊髓灰质炎疫苗的鼻内和舌下给药
Vaccine. 2017 May 9;35(20):2647-2653. doi: 10.1016/j.vaccine.2017.03.090. Epub 2017 Apr 8.
10
Nanotechnologies in Delivery of DNA and mRNA Vaccines to the Nasal and Pulmonary Mucosa.纳米技术在DNA和mRNA疫苗递送至鼻黏膜和肺黏膜中的应用
Nanomaterials (Basel). 2022 Jan 11;12(2):226. doi: 10.3390/nano12020226.
引用本文的文献
1
Inhaled non-viral delivery systems for RNA therapeutics.用于RNA治疗的吸入式非病毒递送系统。
Acta Pharm Sin B. 2025 May;15(5):2402-2430. doi: 10.1016/j.apsb.2025.03.033. Epub 2025 Mar 19.
2
Charge-assisted stabilization of lipid nanoparticles enables inhaled mRNA delivery for mucosal vaccination.电荷辅助稳定脂质纳米粒实现吸入型 mRNA 递送至黏膜用于疫苗接种。
Nat Commun. 2024 Nov 2;15(1):9471. doi: 10.1038/s41467-024-53914-x.
3
Nanoplatform Based Intranasal Vaccines: Current Progress and Clinical Challenges.基于纳米平台的鼻腔内疫苗：当前进展和临床挑战。
ACS Nano. 2024 Sep 10;18(36):24650-24681. doi: 10.1021/acsnano.3c10797. Epub 2024 Aug 26.
4
Nano-Assembled Polyphosphazene Delivery System Enables Effective Intranasal Immunization with Nipah Virus Subunit Vaccine.纳米组装聚磷腈递药系统使尼帕病毒亚单位疫苗经鼻腔免疫更有效。
ACS Appl Bio Mater. 2024 Jun 17;7(6):4133-4141. doi: 10.1021/acsabm.4c00441. Epub 2024 May 30.
5
A comprehensive comparison of DNA and RNA vaccines.DNA 和 RNA 疫苗的全面比较。
Adv Drug Deliv Rev. 2024 Jul;210:115340. doi: 10.1016/j.addr.2024.115340. Epub 2024 May 27.
6
Nanomedicines via the pulmonary route: a promising strategy to reach the target?经肺部途径的纳米药物：一种有前途的靶向给药策略？
Drug Deliv Transl Res. 2024 Aug;14(8):2276-2297. doi: 10.1007/s13346-024-01590-1. Epub 2024 Apr 8.
7
Lipid Nanoparticle-Based Inhibitors for SARS-CoV-2 Host Cell Infection.基于脂质纳米颗粒的 SARS-CoV-2 宿主细胞感染抑制剂。
Int J Nanomedicine. 2024 Mar 28;19:3087-3108. doi: 10.2147/IJN.S448005. eCollection 2024.
8
Pulmonary inhalation for disease treatment: Basic research and clinical translations.用于疾病治疗的肺部吸入：基础研究与临床转化
Mater Today Bio. 2024 Jan 22;25:100966. doi: 10.1016/j.mtbio.2024.100966. eCollection 2024 Apr.
9
A next-generation inhalable dry powder COVID vaccine.一种下一代可吸入式干粉新冠疫苗。
Nature. 2023 Dec;624(7992):532-534. doi: 10.1038/d41586-023-03557-7.
10
Computational fluid dynamics modeling of aerosol particle transport through lung airway mucosa.通过肺气道黏膜的气溶胶颗粒传输的计算流体动力学建模
Comput Chem Eng. 2023 Nov;179. doi: 10.1016/j.compchemeng.2023.108458. Epub 2023 Oct 16.
本文引用的文献
1
Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses.未佐剂化鼻内刺突疫苗引发针对沙贝科病毒的保护性黏膜免疫。
Science. 2022 Nov 25;378(6622):eabo2523. doi: 10.1126/science.abo2523.
2
Operation Nasal Vaccine-Lightning speed to counter COVID-19.鼻喷式新冠疫苗——抗击新冠病毒的“闪电战”。
Sci Immunol. 2022 Aug 12;7(74):eadd9947. doi: 10.1126/sciimmunol.add9947. Epub 2022 Aug 19.
3
Intranasal vaccination with lipid-conjugated immunogens promotes antigen transmucosal uptake to drive mucosal and systemic immunity.鼻腔内接种脂质偶联免疫原可促进抗原经黏膜摄取，从而诱导黏膜和系统免疫。
Sci Transl Med. 2022 Jul 20;14(654):eabn1413. doi: 10.1126/scitranslmed.abn1413.
4
Exosomes decorated with a recombinant SARS-CoV-2 receptor-binding domain as an inhalable COVID-19 vaccine.用带有重组 SARS-CoV-2 受体结合域的外泌体作为可吸入的 COVID-19 疫苗。
Nat Biomed Eng. 2022 Jul;6(7):791-805. doi: 10.1038/s41551-022-00902-5. Epub 2022 Jul 4.
5
A chitosan-mediated inhalable nanovaccine against SARS-CoV-2.一种壳聚糖介导的抗SARS-CoV-2可吸入纳米疫苗。
Nano Res. 2022;15(5):4191-4200. doi: 10.1007/s12274-021-4012-9. Epub 2022 Feb 2.
6
Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses.脂质纳米颗粒通过诱导强烈的滤泡辅助性 T 细胞和体液反应来提高 mRNA 和蛋白亚单位疫苗的效力。
Immunity. 2021 Dec 14;54(12):2877-2892.e7. doi: 10.1016/j.immuni.2021.11.001. Epub 2021 Nov 4.
7
Strategy to enhance dendritic cell-mediated DNA vaccination in the lung.增强肺中树突状细胞介导的DNA疫苗接种的策略。
Adv Ther (Weinh). 2021 Feb;4(2). doi: 10.1002/adtp.202000228. Epub 2021 Feb 24.
8
Intranasal delivery of adjuvant-free peptide nanofibers elicits resident CD8 T cell responses.鼻腔内递送无佐剂肽纳米纤维可引发固有 CD8 T 细胞应答。
J Control Release. 2018 Jul 28;282:120-130. doi: 10.1016/j.jconrel.2018.04.031. Epub 2018 Apr 17.
9
Engineering intranasal mRNA vaccines to enhance lymph node trafficking and immune responses.设计鼻内mRNA疫苗以增强淋巴结转运和免疫反应。
Acta Biomater. 2017 Dec;64:237-248. doi: 10.1016/j.actbio.2017.10.019. Epub 2017 Oct 10.
10
Common gene therapy viral vectors do not efficiently penetrate sputum from cystic fibrosis patients.常见的基因治疗病毒载体不能有效地穿透囊性纤维化患者的痰液。
PLoS One. 2011;6(5):e19919. doi: 10.1371/journal.pone.0019919. Epub 2011 May 27.
Zotero 插件